目的 探讨百令胶囊联合注射用环磷酰胺治疗狼疮性肾炎的临床疗效。方法 选择2017年1月-2018年6月在三二〇一医院进行治疗的狼疮性肾炎患者60例作为研究对象，将患者随机分为对照组和治疗组，每组各30例。对照组患者静脉滴注注射用环磷酰胺，0.5~1.0 g/（m²·月）。治疗组在对照组治疗的基础上口服百令胶囊，2粒/次，3次/d。两组患者均连续治疗6个月。观察两组患者的临床疗效，比较两组治疗前后的24 h尿蛋白定量（24 h Upro）、血清肌酐（Scr）、尿素氮（BUN）水平、系统性红斑狼疮疾病活动指数（SLEDAI）和不良反应。结果 治疗后，对照组和治疗组的总有效率分别为76.67%、96.67%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者24 h Upro、血Scr和BUN水平均明显下降，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组的生化指标水平显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者SLEDAI评分均显著下降，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组的SLEDAI评分显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗期间，对照组和治疗组的不良反应发生率分别为36.7%、10.0%，两组比较差异具有统计学意义（P<0.05）。结论 百令胶囊联合注射用环磷酰胺治疗狼疮性肾炎具有较好的临床疗效，可以改善患者肾功能，降低系统性红斑狼疮活动度，且安全性高，具有一定的临床推广应用价值。

Objective To investigate the clinical effects of Corbrin Capsules combined with Cyclophosphamide for injection in treatment of lupus nephritis. Methods Patients (60 cases) with lupus nephritis in San Er Ling Yi Hospital from January 2017 to June 2018 were randomly divided into control and treatment groups, and each group had 30 cases. Patients in the control group were iv administered with Cyclophosphamide for Injection, 0.5 -1.0 g/m² per month. Patients in the treatment group were po administered with Corbrin Capsules on the basis of control group, 2 grains/time, three times daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacy was evaluated, and the 24 h Upro, Scr, BUN levels and SLEDAI scores in two groups were compared before and after treatment. Results After treatment, the clinical efficacy in the control and treatment groups were 76.67% and 96.67%, respectively, and there were differences between two groups (P < 0.05). After treatment, 24 h U pro, Scr, and BUN levels in two groups were obviously decreased, and there were differences in the same group (P < 0.05). And these biochemical indicators in the treatment group after treatment were significantly lower than those in the control group, and there were differences between two groups (P < 0.05). After treatment, the SLEDAI in two groups was significantly increased, and there were differences in the same group (P < 0.05). And the SLEDAI in the treatment group after treatment was significantly lower than those in the control group, and there were differences between two groups (P < 0.05). During the treatment, the incidence of adverse reactions in the control and treatment groups were 36.7% and 10.0%, respectively, and there were differences between two groups (P < 0.05). Conclusion Corbrin Capsules combined with Cyclophosphamide for injection has a good clinical effect in treatment of lupus nephritis, can improve the renal function of patients, and reduce the activity of systemic lupus erythematosus, with high safety, which has a certain clinical application value.